Reneuron Regulatory News (RENE)

25 August 2015 AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Completion of Placing

and Total Voting Rights

Guildford, UK, 25 August 2015: ReNeuron Group plc, a leading UK-based stem cell therapy company, announced on 21 August 2015 that shareholders had approved all the resolutions in connection with the Placing of £68.4 million before expenses announced in July. As expected, Admission of the Placing shares became effective this morning and dealings commenced at 8.00 a.m.

The Company has 3,156,239,639 Ordinary Shares in issue, all with voting rights. The Company holds no Ordinary Shares in treasury. The figure of 3,156,239,639 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Capitalised terms in this announcement have the same meaning as in the announcement of 10 July 2015 and the circular posted to shareholders on 29 July 2015 except where otherwise indicated.

Enquiries:

ReNeuron +44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer

Cenkos Securities +44 (0) 20 7397 8900

Stephen Keys, Dr Christopher Golden (NOMAD and Broker)

Russell Kerr (Sales)

Buchanan +44 (0) 20 7466 5000

Mark Court, Sophie Cowles, Stephanie Watson

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to enter the clinic in the US.

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.